SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (4718)7/3/1998 1:20:00 AM
From: Peter Singleton  Respond to of 6136
 
Steve, nicely put in your last post ...

<<Admittedly, I do not understand this industry, but I'm not stupid, and
the insider selling, sliding stock price, heavy short interest, lack of
a warm reception of their latest deals, and apparent zero analyst
interest in their pipeline really concern me. Unless there's more
information to come tomorrow on Remune, their earth shattering news does
not appear to have been well received.>>

Yours is an important point of view. Keep posting.

Peter



To: Steve Fancy who wrote (4718)7/3/1998 2:14:00 AM
From: Stewart Whitman  Read Replies (1) | Respond to of 6136
 
Steve,

If you look at AGPH's cash flow statement, you'll see they brought in about $38 million last quarter. Net income was quite deceptive at $13 million. If this cash flow continues for a few more quarters, AGPH should be able to pay for the deals made in the last few weeks relatively easily. Even at lower revenue levels (e.g. previous quarters, AGPH generated substantial positive cash flow).

Stew


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News